Dimethylamine, hydrochloride → 10-bromo-9-fluoro-N3,N3-dimethyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide

HRID 575146ノート

反応式

HRID 575146 の反応式
[Br:1][C:2]1[C:3]([F:22])=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[C:12]([C:18](O)=[O:19])=[C:13]([C:15](=[O:17])[NH2:16])[N:14]=[C:7]3[C:6]=2[CH:21]=1.Cl.[CH3:24][NH:25][CH3:26]>>[Br:1][C:2]1[C:3]([F:22])=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[C:12]([C:18]([N:25]([CH3:26])[CH3:24])=[O:19])=[C:13]([C:15]([NH2:16])=[O:17])[N:14]=[C:7]3[C:6]=2[CH:21]=1

参加物

3

反応物 2

HCID 10473Dimethylamine, hydrochlorideHCID 8669316510-Bromo-2-carbamoyl-9-fluoro-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-3-carboxylic acid

生成物 1

HCID 8669316710-bromo-9-fluoro-N3,N3-dimethyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide

実験手順

10-Bromo-2-carbamoyl-9-fluoro-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-3-carboxylic acid (60 mg) was reacted with dimethylamine Hydrochloride similar to as described in Example 2 to produce crude 10-bromo-9-fluoro-N3,N3-dimethyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide which was then reacted with 2-Methyl-3-butyne-ol similar to as described in Procedure E to afford 41.3 mg of 9-fluoro-10-(3-hydroxy-3-methyl-but-1-ynyl)-N3,N3-dimethyl-5,6-dihydroimidazo[1,2-d][1,4]benz oxazepine-2,3-dicarboxamide following reverse phase hplc purification. MS (Q1) 401 (M)+. 1H NMR (400 MHz, DMSO) δ 8.58 (d, J=8.5 Hz, 1H), 7.68 (s, 1H), 7.24 (s, 1H), 7.02 (d, J=10.5 Hz, 1H), 6.58 (s, 1H), 5.51 (s, 1H), 4.61-4.48 (m, 2H), 4.39-4.12 (m, 2H), 3.01 (s, 3H), 2.88 (s, 3H), 1.49 (s, 6H).

出典と根拠

ORDレコード
ord-bc9e723e2dfa442a8df97ee458bb3c77
出典データセット
uspto-grants-2015_05
特許番号
US09034866B2

反応ノート

読み込み中…